Table 1.
Ruxolitinib dose modifications recommended for MF patients with starting platelet count of at least 100 × 10 9 /L*
| |
Dose at time of decline in platelet count |
Maximum dose based on platelet count after prior treatment interruption or dose reduction | ||||
|---|---|---|---|---|---|---|
|
25 mg BID |
20 mg BID |
15 mg BID |
10 mg BID |
5 mg BID |
||
| Current platelet count | New dose to be used | |||||
| ≥125 × 109/L |
No change |
No change |
No change |
No change |
No change |
20 mg BID |
| 100 to <125 × 109/L |
20 mg BID |
15 mg BID |
No change |
No change |
No change |
15 mg BID |
| 75 to <100 × 109/L |
10 mg BID |
10 mg BID |
10 mg BID |
No change |
No change |
10 mg BID for 2 weeks; if stable, may increase to 15 mg BID |
| 50 to <75 × 109/L |
5 mg BID |
5 mg BID |
5 mg BID |
5 mg BID |
No change |
5 mg BID for 2 weeks; if stable, may increase to 10 mg BID |
| <50 × 109/L | Hold | Hold | Hold | Hold | Hold | Continue holding |
*Starting ruxolitinib doses of 15 mg BID for patients with platelet counts of 100 to 200 × 109/L and 20 mg BID for those with a platelet count >200 × 109/L. Recommended dose modifications based on US prescribing information.
For insufficient response, doses may be increased in 5-mg BID increments to a maximum of 25 mg BID, provided that platelet and neutrophil counts are adequate.
BID, twice daily; MF, myelofibrosis.
Data from Jakafi prescribing information (Incyte Corporation, June 2013).
See full prescribing information for a complete description of FDA-approved dosing of ruxolitinib in patients with intermediate or high-risk MF.